Uncategorized
Trump’s ‘most favored nation’ policy threatens US competitiveness with China
Congressional enactment of the “most favored nation” drug pricing policy urged by President Donald Trump in his State of the Union message would gravely harm American innovation, competitiveness, and national security in the emerging pharmaceutical technology race with China by crippling the market incentive system that has reliably propelled U.S. global leadership in this vital sector for decades. MFN policies are price-control schemes that establish caps on the costs of prescription drugs sold in the United States based on…
